Sanofi (SNY)
| Market Cap | 116.93B |
| Revenue (ttm) | 51.60B |
| Net Income (ttm) | 6.00B |
| Shares Out | 2.40B |
| EPS (ttm) | 2.32 |
| PE Ratio | 25.82 |
| Forward PE | 11.14 |
| Dividend | $2.04 (4.18%) |
| Ex-Dividend Date | May 9, 2024 |
| Volume | 1,118,872 |
| Open | 48.19 |
| Previous Close | 48.06 |
| Day's Range | 48.10 - 48.82 |
| 52-Week Range | 42.63 - 55.72 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 55.00 (+12.96%) |
| Earnings Date | Apr 25, 2024 |
About SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines... [Read more]
Financial Performance
In 2023, Sanofi's revenue was 46.44 billion, an increase of 2.32% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to one analyst, the rating for SNY stock is "Hold" and the 12-month stock price forecast is $55.0.
News
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respirator...
Press Release: Annual General Meeting of April 30, 2024
Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023 Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024 Board composi...
Sanofi CEO Paul Hudson on Q1 results: Hope to gather even more momentum later this year
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, and more.
Sanofi Sales, Profit Beat Forecasts
Sanofi backed its full-year earnings guidance after it reported first-quarter profit ahead of consensus, with sales growth driven by continued strength in anti-inflammatory drug Dupixent and its new d...
Sanofi Q1 profit slips on generic competition, forex effects
Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflam...
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS (1) of €1.78 Dupixent sales up 24.9% to €2,835 mil...
FTC looking to accelerate inquiry into prescription-drug middlemen, chair says
The Federal Trade Commission is working to accelerate its inquiry into the prescription-drug middlemen known as pharmacy-benefit managers, while also expanding its scrutiny of drug patents that can ke...
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilz...
Sanofi to overhaul US operations of vaccines, cut jobs
French drugmaker Sanofi said on Thursday it would restructure the U.S. commercial operations for its vaccines and cut an undisclosed number of jobs.
COTA Announces Strategic Collaboration with Sanofi to Leverage Real-World Data and AI to Accelerate Cancer Trials
NEW YORK--(BUSINESS WIRE)--COTA, a leader in real-world data (RWD) and analytics for oncology, today announced a strategic collaboration with Sanofi to use RWD and artificial intelligence (AI) to incr...
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting t...
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
Sanofi - AGM 30.04.2024 - Availability of Preparatory documents
COMBINED GENERAL MEETING OF APRIL 30, 2024 AVAILABILITY OF PREPARATORY DOCUMENTS The Company's shareholders are invited to attend the Combined General Meeting to be held on Thursday April 30, 2024 at ...
Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups
READING, U.K.--(BUSINESS WIRE)--Sanofi launches Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for pre-exposure and post-exposure prophylaxis of rabies in all age groups.
Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial
The drug, made by Sanofi, is a GLP-1 like Novo Nordisk's blockbuster diabetes injection Ozempic and weight loss counterpart Wegovy
Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial
A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the Ne...
Sanofi to Settle Claims That Heartburn Drug Zantac Caused Cancer
The French healthcare company said the deal would require the consent of individual plaintiffs and would take time to conclude.
Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts
Sanofi has reached an agreement in principle to settle 4,000 lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
Availability of the Q1 2024 Memorandum for modelling purposes Paris, France – March 22, 2024. Sanofi announced today that its Q1 2024 Memorandum for modelling purposes is available on the "Investors" ...
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study shows
AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a study by the U.S. Centers of Disease Contro...
‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?
Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed...
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Filing of the 2023 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, February 23, 2024. Sanofi announces today the filing of its Form 20-F w...